Janku et al. reported that among patients affected by advanced breast, cervical, endometrial, and ovarian cancers, those with PIK3CA mutations treated with PI3K/AKT/mTOR inhibitors demonstrated a higher response rate than patients without mutations [30]. Here, PIK3CA is linked to ovarian cancer.